Short-Term Traders Should Check Out Regeneron (REGN)

Regeneron Pharmaceuticals REGN has been offering up some terrific day trading opportunities in the last couple of sessions after some positive Phase III data for its drug ZALTRAP for second-line Metastatic Colorectal Cancer. The stock surged around 28% yesterday and has already made some big moves on Thursday. Currently, REGN shares are down 4.85% to $63.79. On a longer term basis, REGN has been a tremendous performer, gaining 160% in the last year. Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions.